{
    "symbol": "NYXH",
    "quarter": 4,
    "year": 2022,
    "date": "2023-03-22 21:26:04",
    "content": " Now I would like to share our three key objectives for 2023; first is to focus on patient follow-up in the DREAM study, resulting in reaching the primary end points; next is beginning preparations to enter the U.S. market with regulatory manufacturing and market access readiness; and last is driving further revenue growth in Germany and opening new European markets. I would like to reiterate our key objectives for 2023, which are focusing on patient follow-up in the DREAM study, resulting in reaching the primary end points; beginning preparations to enter the U.S. market with regulatory, manufacturing and market access readiness; and driving further revenue growth in Germany, while opening additional European markets."
}